Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Giant Cell Tumor of Tendon Sheath 5Synovitis, Pigmented Villonodular 3Melanoma 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Solid Tumor 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neoplasms 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Ipilimumab 98pembrolizumab 84Nivolumab 82aldesleukin 51Cyclophosphamide 49Interleukin-2 38fludarabine phosphate 31Vemurafenib 31Dacarbazine 31dabrafenib 29trametinib 28Temozolomide 26fludarabine 25CTLA-4 Antigen 18Bevacizumab 18Radiosurgery 15Paclitaxel 15Carboplatin 14encorafenib 13binimetinib 13Introns 13talimogene laherparepvec 12Radiotherapy 12Interferon alpha-2 12spartalizumab 11cobimetinib 10atezolizumab 10sargramostim 9peginterferon alfa-2b 9montanide ISA 51 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Melanoma × pexidartinib × Clear all
NCT02975700 2026-01-13

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

Daiichi Sankyo

Phase NA Completed
6 enrolled 21 charts
Dermatologic

Melanoma

NCT02452424 2020-03-05

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Daiichi Sankyo

Phase 1/2 Terminated
78 enrolled 19 charts
DermatologicGastrointestinalGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡